Soy isoflavones prevent ovariectomy-induced atherosclerotic lesions in Golden Syrian hamster model of postmenopausal hyperlipidemia

Menopause

Volumn 10, Issue 4, 2003, Pages 314-321

  Lucas, Edralin A ^a   Lightfoot, Stanley A ^b   Hammond, Lisa J ^a   Devareddy, Latha ^a   Khalil, Dania A ^a   Daggy, Bruce P ^a   Soung, Do Y ^a   Arjmandi, Bahram H ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Hamsters; Isoflavones; Lipids; Menopause; Ovariectomy

Indexed keywords

CHOLESTEROL; ISOFLAVONE; LIPID;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY WEIGHT; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; HORMONE DEFICIENCY; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE; SOYBEAN;

EID: 0037489731     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GME.0000051509.84118.FD     Document Type: Article

References (60)

1. Kessler KM. Postmenopausal hormone therapy and cardiovascular disease. Ann Intern Med 2001;35:1092-1093.
2. Matthews KA, Kuller LH, Sutton-Tyrrell K, Chang YF. Changes in cardiovascular risk factors during the perimenopause and post-menopause and carotid artery atherosclerosis in healthy women. Stroke 2001;32:1104-1111.
3. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-313.
4. Barrett-Connor E. Prevalence, initiation, and continuation of hormone replacement therapy. J Womens Health 1995;4:143-148.
5. White JP, Schilling J. Postmenopausal hormone replacement: historical perspectives and current concerns. Clin Excell Nurse Pract 2000;4:277-285.
6. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1997;156:1332-1334.
7. United States Department of Health and Human Services. Second Report of the Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults. NIH Publication No. 93-3095. Bethesda, MD: NHLBI Information Center, 1993.
8. Boger RH. Drug interactions of the statins and consequences for drug selection. Int J Clin Pharmacol Ther 2001;39:369-382.
9. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995;333:276-282.
10. Crouse JR, Morgan T, Terry JG, Ellis J, Vitolins M, Burke GL. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med 1999;159:2070-2076.
11. Han KK, Soares JM Jr, Haidar MA, de Lima GR, Baracat EC. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol 2002;99:389-394.
12. Hermansen K, Sondergaard M, Hoie L, Carstensen M, Brock B. Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects. Diabetes Care 2001;24:228-233.
13. Merz-Demlow BE, Duncan AM, Wangen KE, et al. Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women. Am J Clin Nutr 2000;71:1462-1469.
14. Wong WW, Smith EO, Stuff JE, Hachey DL, Heird WC, Pownell HJ. Cholesterol-lowering effect of soy protein in normocholesterolemic and hypercholesterolemic men. Am J Clin Nutr 1998;68:1385S-1389S.
15. Washburn S, Burke GL, Morgan T, Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 1999;6:7-13.
16. Nestel PJ, Yamashita T, Sasahara T, et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol 1997;17:3392-3398.
17. Tikkanen MJ, Wahala K, Ojala S, Vihma V, Adlercreutz H. Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance. Proc Natl Acad Sci U S A 1998;95:3106-3110.
18. 2-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. Am J Clin Nutr 2000;72:395-400.
19. Anthony MS, Clarkson TB, Bullock BC, Wagner JD. Soy protein versus phytoestrogens in the prevention of diet-induced coronary atherosclerosis of male cynomolgus monkeys. Arterioscler Thromb Vasc Biol 1997;17:2524-2531.
20. Kirk EA, Sutherland P, Wang SA, Chait A, LeBoeuf RC. Dietary isoflavones reduce plasma cholesterol and atherosclerosis in C57BL/6 mice but not LDL receptor-deficient mice. J Nutr 1998;28:954-959.
21. Yamakoshi J, Piskula MK, Izumi T, et al. Isoflavone aglycone rich extract without soy protein attenuates atherosclerosis development in cholesterol-fed rabbits. J Nutr 2000;130:1887-1893.
22. Hodgson JM, Puddey IB, Beilin LJ, Mori TA, Croft KD. Supplementation with isoflavonoid phytoestrogens does not alter serum lipid concentrations: a randomized control trials in humans. J Nutr 1998;128:728-732.
23. Simons LA, von Konigsmark M, Simons J, Celermajer DS. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am J Cardiol 2000;85:1297-1301.
24. Greaves KA, Parks JS, Williams JK, Wagner JD. Intact dietary soy protein, but not adding an isoflavone-rich soy extract to casein, improves plasma lipids in ovariectomized cynomolgus monkeys. J Nutr 1999;129:1585-1592.
25. Alexandersen P, Haarbo J, Breinholt V, Christiansen C. Dietary phytoestrogens and estrogen inhibit experimental atherosclerosis. Climacteric 2001;4:151-159.
26. Adams MR, Golden DL, Anthony MS, Register TC, Williams JK. The inhibitory effect of soy protein isolate on atherosclerosis in mice does not require the presence of LDL receptors or alteration of plasma lipoproteins. J Nutr 2002;132:43-49.
27. Ni W, Tsuda Y, Sakono M, Imaizumi K. Dietary soy protein isolate, compared with casein, reduces atherosclerotic lesion area in apolipoprotein E-deficient mice. J Nutr 1998;128:1884-1889.
28. Sohn E, Daggy BP, Arjmandi BH. Ovariectomized hamster: a potential model of postmenopausal hypercholesterolemia. J Nutr Biochem 1999;10:660-663.
29. Lucas EA, Khalil DA, Daggy BP, Arjmandi BH. Ethanol-extracted soy protein isolate does not modulate serum cholesterol in Golden Syrian hamsters: a model of postmenopausal hypercholesterolemia. J Nutr 2001;131:211-214.
30. Nistor A, Bulla A, Filip DA, Radu A. The hyperlipidemic hamster as a model of experimental atherosclerosis. Atherosclerosis 1987;68:159-173.
31. Wilson TA, Nicolosi RJ, Lawton CW, Babiak J. Gender differences in response to a hypercholesterolemic diet in hamsters: effects on plasma lipoprotein cholesterol concentrations and early aortic atherosclerosis. Atherosclerosis 1999;146:83-91.
32. Vinson JA, Teufel K, Wu N. Red wine, dealcoholized red wine, and especially grape juice, inhibit atherosclerosis in a hamster model. Atherosclerosis 2001;156:67-72.
33. Searcy RL, Bergquist LM. A new color reaction for the quantitation of serum cholesterol. Clin Chim Acta 1960;5:192-199.
34. Folch J, Lees M, Sloane-Stanley GH. A simple method for isolation and purification of total lipids from animal tissue. J Biol Chem 1957;226:497-509.
35. Auger C, Caporiccio B, Landrault N, et al. Red wine phenolic compounds reduce plasma lipids and apolipoprotein B and prevent early aortic atherosclerosis in hypercholesterolemic golden Syrian hamsters (Mesocricetus auratus). J Nutr 2002;132:1207-1213.
36. Lassila HC, Tyrrell KS, Matthews KA, Wolfson SK, Kuller LH. Prevalence and determinants of carotid atherosclerosis in healthy postmenopausal women. Stroke 1997;28:513-517.
37. Massart F, Reginster JY, Brandi ML. Genetics of menopause-associated diseases. Maturitas 2001;40:103-116.
38. Robins SJ, Fasulo JM, Patton GM, Schaefer EJ, Smith DE, Ordovas JM. Gender differences in the development of hyperlipemia and atherosclerosis in hybrid hamsters. Metabolism 1995;44:1326-1331.
39. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;390:915-924.
40. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-1792.
41. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996;20:707-727.
42. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992;13:341-390.
43. Berliner JA, Territo MC, Sevanian A, et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990;85:1260-1266.
44. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation 1995;91:2488-2496.
45. Ruiz-Larrea MB, Mohan AR, Paganga G, Miller NJ, Bolwell GP, Rice-Evans CA. Antioxidant activity of phytoestrogenic isoflavones. Free Radic Res 1997;26:63-70.
46. Kapiotis S, Hermann M, Held I, Seelos C, Ehringer H, Gmeiner BM. Genistein, the dietary-derived angiogenesis inhibitor, prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL. Arterioscler Thromb Vasc Biol 1997;17:2868-2674.
47. Arora A, Nair MG, Strasburg GM. Antioxidant activities of isoflavones and their biological metabolites in a liposomal system. Arch Biochem Biophys 1998;356:133-141.
48. Tiidus PM. Can estrogens diminish exercise induced muscle damage? Can J Appl Physiol 1995;20:26-38.
49. Pervin S, Singh R, Rosenfeld ME, Navab M, Chaudhuri G, Nathan L. Estradiol suppresses MCP-1 expression in vivo: implications for atherosclerosis. Arterioscler Thromb Vasc Biol 1998;18:1575-1582.
50. Frazier-Jessen MR, Kovacs EJ. Estrogen modulation of JE/monocyte chemoattractant protein-1 mRNA expression in murine macrophages. J Immunol 1995;154:1838-1845.
51. Nakai K, Itoh C, Hotta K, Itoh T, Yoshizumi M, Hiramori K. Estradiol-17 beta regulates the induction of VCAM-1 mRNA expression by interleukin-1 beta in human umbilical vein endothelial cells. Life Sci 1994;54:PL221-PL2217.
52. Stein B, Yang MX. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol 1995;15:4971-4979.
53. Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 1996;98:36-42.
54. Raines EW, Ross R. Biology of atherosclerotic plaque formation: possible role of growth factors in lesion development and the potential impact of soy. J Nutr 1995;125(Suppl):624S-630S.
55. Makela S, Savolainen H, Aavik E, et al. Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors alpha and beta. Proc Natl Acad Sci USA 1999;96:7077-7082.
56. Shimokado K, Umezawa K, Ogata J. Tyrosine kinase inhibitors inhibit multiple steps of the cell cycle of vascular smooth muscle cells. Exp Cell Res 1995;220:266-273.
57. Shimokado K, Yokota T, Umezawa K, Sasaguri T, Ogata J. Protein tyrosine kinase inhibitors inhibit chemotaxis of vascular smooth muscle cells. Arterioscler Thromb 1994;14:973-981.
58. Honore EK, Williams JK, Anthony MS, Clarkson TB. Soy isoflavones enhance vascular reactivity in atherosclerotic female macaques. Fertil Steril 1997;67:148-154.
59. Williams JK, Clarkson TB. Dietary isoflavones inhibit in vivo constrictor response of coronary arteries to collagen-induced platelet activation. Coron Artery Dis 1998;9:759-764.
60. Schoene NW, Guidry CA. Dietary isoflavones inhibit activation of rat platelets. J Nutr Biochem 1999;10:421-426.